Orchestra BioMed Holdings (OBIO) Net Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Net Margin of 18778.18% for Q1 2026, down 1661747.0% year-over-year from N/an in Q1 2025, and down 90912.61% quarter-over-quarter from 20.68% in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Net Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Net Margin for 5 consecutive years, with 18778.18% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 1661747.0% year-over-year to 18778.18%; the TTM figure through Mar 2026 stood at 172.26% (up 251877.0% YoY), while the FY2025 annual figure was 158.16%, up 215511.0% from the prior year.
- Net Margin retreated to 18778.18% in Q1 2026 per OBIO's latest filing, from 20.68% in the prior quarter.
- Across five years, Net Margin topped out at 20.68% in Q4 2025 and bottomed at 18778.18% in Q1 2026.
- Historically, Net Margin has averaged 3359.54% across 5 years, with a median of 2160.71% in 2025.
- Annual changes were most pronounced in 2025 — Net Margin soared 638352 bps — and 2026, when it slumped 1661747 bps.
- Orchestra BioMed Holdings' Net Margin stood at 914.6% in 2022, then slumped by 421 bps to 4763.74% in 2023, then sank by 34 bps to 6362.85% in 2024, then soared by 100 bps to 20.68% in 2025, then sank by 90913 bps to 18778.18% in 2026.
- Business Quant data shows OBIO's Net Margin at 18778.18% in Q1 2026, 20.68% in Q4 2025, and 2385.37% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -27,362.50% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27,362.50% |
| Mar 31, 2026 | -18,778.18% |
| Dec 31, 2025 | 19.38% |
| Sep 30, 2025 | -2,419.05% |
| Jun 30, 2025 | -2,316.15% |
| Mar 31, 2025 | -2,160.71% |
| Dec 31, 2024 | -6,385.38% |
| Sep 30, 2024 | -1,562.92% |
| Jun 30, 2024 | -2,051.03% |
| Mar 31, 2024 | -2,162.42% |
| Dec 31, 2023 | -4,340.84% |
| Sep 30, 2023 | -3,247.97% |
| Jun 30, 2023 | -1,415.96% |
| Mar 31, 2023 | -991.84% |
| Dec 31, 2022 | -891.02% |
| Sep 30, 2022 | -865.61% |
| Jun 30, 2022 | -1,903.74% |
| Mar 31, 2022 | -592.15% |